DOJ's Bureau of Prisons awards $25.2M for FY26 Flu Vaccine to Sanofi
Contract Overview
Contract Amount: $2,522 ($2.5K)
Contractor: Sanofi Vaccines US Inc.
Awarding Agency: Department of Justice
Start Date: 2026-04-09
End Date: 2026-09-30
Contract Duration: 174 days
Daily Burn Rate: $14/day
Competition Type: FULL AND OPEN COMPETITION
Pricing Type: FIRM FIXED PRICE
Sector: Healthcare
Official Description: B1 - FLU VACCINE FY26
Place of Performance
Location: SWIFTWATER, MONROE County, PENNSYLVANIA, 18370
Plain-Language Summary
Department of Justice obligated $2,521.8 to SANOFI VACCINES US INC. for work described as: B1 - FLU VACCINE FY26 Key points: 1. Significant contract for essential public health service within federal correctional facilities. 2. Competition method is 'Full and Open', suggesting potential for competitive pricing. 3. Risk of supply chain disruptions or vaccine efficacy concerns are inherent. 4. Pharmaceutical sector spending is substantial and closely monitored for value.
Value Assessment
Rating: good
The award amount of $25.2M for FY26 flu vaccines appears reasonable given the scale of the federal prison system. Benchmarking against similar large-scale pharmaceutical procurements would provide a more precise assessment.
Cost Per Unit: N/A
Competition Analysis
Competition Level: full-and-open
The contract was awarded under full and open competition, which typically drives competitive pricing and ensures the government receives the best value. The delivery order structure allows for flexibility in procurement.
Taxpayer Impact: Taxpayer funds are being used to ensure the health and safety of inmates and staff, a necessary expenditure for public health and security.
Public Impact
Ensures health and safety of inmates and staff within federal prisons. Supports national public health initiatives by securing vaccine supply. Potential for cost savings through competitive bidding process.
Waste & Efficiency Indicators
Waste Risk Score: 50 / 10
Warning Flags
- Potential for price fluctuations in pharmaceutical markets.
- Dependence on a single supplier for a critical health product.
- Logistical challenges in vaccine distribution to multiple facilities.
Positive Signals
- Proactive procurement for upcoming fiscal year.
- Use of competitive bidding process.
- Focus on essential public health service.
Sector Analysis
The pharmaceutical sector is characterized by high R&D costs, complex manufacturing, and significant regulatory oversight. Federal spending in this area often focuses on essential medicines and vaccines for public health programs and government facilities.
Small Business Impact
This contract does not appear to have specific provisions for small business participation, as it was awarded under full and open competition. Further analysis would be needed to determine if subcontracting opportunities exist for small businesses.
Oversight & Accountability
The Department of Justice's Bureau of Prisons is responsible for this procurement. Oversight would involve monitoring contract performance, delivery schedules, and adherence to quality standards to ensure taxpayer value and public health objectives are met.
Related Government Programs
- Pharmaceutical Preparation Manufacturing
- Department of Justice Contracting
- Federal Prison System / Bureau of Prisons Programs
Risk Flags
- Potential for price increases in subsequent years.
- Dependence on a single manufacturer.
- Logistical challenges in distribution.
- Vulnerability to global pharmaceutical supply chain disruptions.
Tags
pharmaceutical-preparation-manufacturing, department-of-justice, pa, delivery-order, under-100k
Frequently Asked Questions
What is this federal contract paying for?
Department of Justice awarded $2,521.8 to SANOFI VACCINES US INC.. B1 - FLU VACCINE FY26
Who is the contractor on this award?
The obligated recipient is SANOFI VACCINES US INC..
Which agency awarded this contract?
Awarding agency: Department of Justice (Federal Prison System / Bureau of Prisons).
What is the total obligated amount?
The obligated amount is $2,521.8.
What is the period of performance?
Start: 2026-04-09. End: 2026-09-30.
What is the historical cost per dose for flu vaccines procured by the Bureau of Prisons or similar agencies?
Historical cost data per dose is crucial for evaluating the value of this $25.2M award. Benchmarking against previous years' procurements by the Bureau of Prisons or other federal health agencies like the Department of Defense or HHS would reveal if Sanofi's pricing is competitive or if there has been a significant cost increase. This analysis helps determine if the current contract represents good value for taxpayer money.
What are the specific risks associated with relying on Sanofi for the entire FY26 flu vaccine supply for federal prisons?
Reliance on a single supplier like Sanofi for the entire FY26 flu vaccine supply introduces risks such as potential manufacturing delays, quality control issues, or unforeseen supply chain disruptions. If Sanofi faces production problems, the Bureau of Prisons could face a critical shortage, impacting inmate and staff health. Diversification of suppliers or contingency planning would mitigate these risks.
How effectively does this vaccine procurement contribute to the overall health and operational stability of the federal prison system?
This procurement is vital for maintaining the health and operational stability of the federal prison system by preventing widespread influenza outbreaks, which can strain medical resources and disrupt facility operations. Ensuring timely and adequate vaccine supply protects both inmates and staff, reducing absenteeism and healthcare costs associated with flu-related illnesses. Effective distribution and administration are key to realizing these benefits.
Industry Classification
NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing
Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP
Competition & Pricing
Extent Competed: FULL AND OPEN COMPETITION
Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE
Pricing Type: FIRM FIXED PRICE (J)
Evaluated Preference: NONE
Contractor Details
Parent Company: Sanofi
Address: 1 DISCOVERY DR, SWIFTWATER, PA, 18370
Business Categories: Category Business, Corporate Entity Not Tax Exempt, Foreign Owned, Foreign-Owned and U.S.-Incorporated Business, Manufacturer of Goods, Not Designated a Small Business, Special Designations
Financial Breakdown
Contract Ceiling: $2,522
Exercised Options: $2,522
Current Obligation: $2,522
Contract Characteristics
Commercial Item: COMMERCIAL PRODUCTS/SERVICES
Cost or Pricing Data: NO
Parent Contract
Parent Award PIID: 36E79726D0009
IDV Type: IDC
Timeline
Start Date: 2026-04-09
Current End Date: 2026-09-30
Potential End Date: 2026-09-30 00:00:00
Last Modified: 2026-04-09
More Contracts from Sanofi Vaccines US Inc.
- 00hcvgbc-2009-68767 - Sanofi VFC Pediatric Vaccine Contract — $737.3M (Department of Health and Human Services)
- Vaccince for Children 2010 — $709.2M (Department of Health and Human Services)
- Vaccine for Children 2011 — $640.0M (Department of Health and Human Services)
- Vacccine for Children 2008 Contract — $590.5M (Department of Health and Human Services)
- VFC 2012 — $589.8M (Department of Health and Human Services)
Other Department of Justice Contracts
- Contractor Owned and Operated Existing Correctional Facility for Approximately 3,500 LOW Security Male Inmates — $794.5M (Cornell Companies, Inc.)
- Detention Services - SAN Diego — $776.9M (THE GEO Group, Inc.)
- CO: Telly Renfroe Award of NEW Task Order Base Year Initial Funding — $616.4M (AT&T Enterprises, LLC)
- TAS 151060 - Services for the Management and Operation of a Contractor-Owned, Contractor-Operated, Correctional Facility for 2,567 Beds in Adams County, Mississippi — $574.3M (Corecivic, Inc.)
- Provide Services for the Management and Operation of a Correctional Facility in Accordance With Rfp-Pcc-0014 — $568.9M (Cornell Companies, Inc.)